繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment

2024-09-04 00:40

12:40 PM EDT, 09/03/2024 (MT Newswires) -- BioVie (BIVI) said Tuesday the US Food and Drug Administration has authorized its investigational new drug application to evaluate bezisterim for treating neurological symptoms associated with long COVID.

The approval allows BioVie to proceed with a phase 2 trial and positions the company to receive an additional $12.6 million in grant funding from the US Department of Defense, the company said.

The trial will assess the safety and efficacy of bezisterim, an anti-inflammatory treatment, in addressing long COVID's neurocognitive symptoms, BioVie said.

BioVie shares were down 5% in recent trading.

Price: 2.64, Change: -0.14, Percent Change: -5.04

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。